Generic Semaglutide Enters pCPA Tier at 85% of Brand Reference

Single-source generic semaglutide enters Canada's pan-Canadian Pharmaceutical Alliance (pCPA) tiered framework at 85% of the brand reference price — or 75% if a pricing agreement with provincial plans exists — before automatically dropping to 55% after three months of public funding [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription].

How the pCPA tiers apply to semaglutide

According to a breakdown published by Endor Health, the pCPA framework sets generic injectable pricing in steps tied to how many manufacturers are active in the Canadian market. A single-source generic enters at 85% of the brand reference price, falling to 55% after three months of public funding. Two generics drop both prices to 50% of brand reference. Three or more generics for injectables like semaglutide brings the price to 35% of brand reference [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription].

That framework governs what provincial public drug plans pay, not what patients pay directly at the pharmacy counter. Actual out-of-pocket costs depend on insurance coverage, whether the relevant province has listed the generic on its formulary, and the retail pricing set by individual pharmacies [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription].

Two generics now approved, seven pending

Health Canada approved Dr. Reddy's Laboratories' generic semaglutide on April 28, 2026 — the first generic semaglutide authorized in Canada and the first in any G7 country [Source: glp1prices.ca/generic-alert]. Apotex followed on May 1, 2026, with approval for Apo-Semaglutide Injection, the second generic authorized in Canada [Source: glp1prices.ca/generic-alert]. Both approvals reference Ozempic as the comparator and cover the Type 2 diabetes indication only [Source: glp1prices.ca/generic-alert].

Seven additional generic semaglutide submissions remain under Health Canada review as of May 2026 [Source: glp1prices.ca/generic-alert]. Health Canada confirmed it is reviewing nine submissions for generic versions of semaglutide overall [Source: cbc.ca/news/health/ozempic-glp1-health-canada-generic-9.7034498]. No generic equivalent to Wegovy has been approved; the regulatory path is open but no manufacturer has filed an Abbreviated New Drug Submission referencing Wegovy at the higher 2.4 mg dose [Source: glp1prices.ca/generic-alert].

What patients should expect at the pharmacy

For most patients covered by private insurance, the transition to generic semaglutide will likely happen at the pharmacy level without requiring patient action [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription]. Insurers typically update their formularies to list the generic as the preferred product, meaning a pharmacist may dispense the generic version at the next refill unless the physician has specified the brand-name product is medically necessary [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription].

Patients may also request the brand-name product based on personal preference, though this will often result in higher out-of-pocket costs if the insurer has designated the generic as the preferred product [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription]. For patients covered by provincial public drug plans, the transition is generally more structured: provincial plans typically move to reimburse only the generic once available, though timelines and listing decisions vary by province [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription].

March 2026 cardiovascular indication

On March 2, 2026, Health Canada approved a new indication for Ozempic: reducing the risk of major adverse cardiovascular events in adults with Type 2 diabetes who also have established cardiovascular disease or chronic kidney disease [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription]. The new indication does not change the existing approved use for blood sugar management [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription].

Bioequivalence standard

Health Canada has confirmed that both approved generics are pharmaceutically equivalent to Ozempic, and that differences between the generic and brand-name products do not affect safety, efficacy, or quality [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription]. To receive authorization, generic semaglutide manufacturers must demonstrate that their product contains the same active ingredient at the same strength and dose, works the same way in the body, and meets the same safety, efficacy, and quality standards as the brand-name version [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription].

Semaglutide is a synthetic peptide delivered by injection rather than a conventional small-molecule pill, which is why Health Canada's review process involved additional scrutiny and generic approval took longer than for most drug classes [Source: endorhealth.com/article/generic-ozempic-approved-canada-prescription]. Patients can monitor approval status on the generic semaglutide tracker, check plan terms via the insurance coverage checker, or review the FAQ for additional context. Patients prescribed Mounjaro, Zepbound, or Rybelsus are not affected by the semaglutide generic approvals, as those products are not the subject of the current generic submissions [Source: glp1prices.ca/generic-alert].

This article is for informational purposes only and does not constitute medical advice.